Jiangsu HengRui Medicine Co., Ltd.: Diabetes Mellitus trials

The registry lists 22 Diabetes Mellitus studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 10Phase 2 8Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic FunctionRecruitingNCT07540754Phase 1
• A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 InjectionRecruitingNCT07489482Phase 1
• Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT06961643Phase 1
• Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy HumanCompletedNCT06727838Phase 1
• Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes SubjectsCompletedNCT05966272Phase 2
• A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes MellitusStatus unknownNCT05759897Phase 2
• To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.CompletedNCT05702073Phase 3
• To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DrugsCompletedNCT05699408Phase 3
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusCompletedNCT05516966Phase 1
• A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 DiabetesStatus unknownNCT05333835Phase 2
• Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin MonotherapyStatus unknownNCT04667143Phase 3
• A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral AntidiabeticsCompletedNCT04663282Phase 2
• A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.CompletedNCT03848793Phase 2
• Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal InsufficientStatus unknownNCT03159832Phase 1
• The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes PatientsStatus unknownNCT02822534Phase 1
• The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus PatientsStatus unknownNCT02366377Phase 1
• The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus PatientsStatus unknownNCT02366351Phase 1
• Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus PatientsCompletedNCT02346175Phase 1
• Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT01984489Phase 2
• A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 DiabetesStatus unknownNCT01970046Phase 3
• A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 DiabetesCompletedNCT01969357Phase 2
• Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT01969318Phase 2